ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023. The increase of $10.2 million was primarily driven ...

The following is a summary of "Vascular Remodeling and TSLP/Angiogenin Overexpression in Severe Mixed Asthma," published in the February 2025 issue of the Respiratory Research by Bertolini et al.

Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia ...

不久前，华福证券发布医药生物行业研报称：全球虽仅一款TSLP单抗上市，但2024年销售额有望突破10亿美元，胸腺基质淋巴细胞生成素即TSLP是IL-2类多效能细胞因子，在免疫反应尤其是二型免疫反应中发挥重要作用，参与过敏性疾病、慢性炎症性疾病等过程。

Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal ...

同期在上述大会上公布的Ⅲ期DIRECTION研究结果显示，在亚洲地区重度未控制哮喘患者中，与使用安慰剂相比，特泽利尤单抗治疗52周可使年哮喘急性发作率显著降低74%。与该药的全球数据一致，特泽利尤单抗治疗组患者的肺功能、哮喘控制水平及健康相关生活质量亦较安慰剂组呈现显著改善。DIRECTION研究中，特泽利尤单抗的安全性特征及耐受性与已获批的重度哮喘适应症一致。

金融界3月5日消息， 健康元 （ 600380 ）披露投资者关系活动记录表显示，公司在 AI 制药领域积极探索，目前深度聚焦 AI 技术应用与创新，助力分子发现、药学研究、临床研究等关键环节，全面提升研发效率并降低成本。同时，公司正加速推动 TSLP 单抗的 II ...

本次2025 ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...